Effects of OnabotulintoxinA on Habituation of Laser Evoked Responses in Chronic Migraine

Toxins (Basel). 2016 May 25;8(6):163. doi: 10.3390/toxins8060163.

Abstract

Onabotulintoxin A (BontA) is an efficacious preventive treatment for chronic migraine, though the specific mechanism of action is still under discussion. The study aims: (1) To evaluate pain processing modifications in chronic migraine patients (CM) under single BontA administration in pericranial muscles, by means of CO² Laser Evoked Potentials (LEPs) obtained by the stimulation of the skin over the right frontal and trapezius injection sites and hand dorsum, in a double blind placebo controlled crossover design. (2) To correlate main LEPs findings with clinical outcome after one year of BontA treatment. Twenty refractory CM patients were included in the analysis. The LEPs were recorded in basal conditions and seven days after BontA (PREEMPT protocol) and saline solution injection. The N1, N2 and P2 amplitude and latencies and N2P2 habituation index were evaluated and correlated with the percent change of headache frequency after one year of toxin treatment. After seven days of BontA treatment, a normalization of the trigeminal habituation index was observed, which was correlated with the clinical outcome after one year of BontA therapy. Patients displaying trigeminal LEPs facilitation at T0 time showed a more efficient therapeutic outcome. Neurotoxin may exert a modulating effect on trigeminal nociception, normalizing central neurotransmission.

Keywords: chronic migraine; laser evoked potentials; neurotoxin mechanism.

Publication types

  • Randomized Controlled Trial

MeSH terms

  • Botulinum Toxins, Type A / administration & dosage
  • Botulinum Toxins, Type A / therapeutic use*
  • Chronic Disease
  • Cross-Over Studies
  • Double-Blind Method
  • Female
  • Habituation, Psychophysiologic / drug effects*
  • Habituation, Psychophysiologic / physiology
  • Headache / drug therapy
  • Headache / physiopathology
  • Humans
  • Laser-Evoked Potentials / drug effects*
  • Male
  • Middle Aged
  • Migraine Disorders / drug therapy*
  • Migraine Disorders / physiopathology
  • Pain Measurement
  • Pain Threshold
  • Physical Stimulation
  • Recurrence
  • Surveys and Questionnaires
  • Treatment Outcome

Substances

  • Botulinum Toxins, Type A